User profiles for Alexandre B Cavalcanti

Alexandre Cavalcanti

Diretor, Instituto de Pesquisa, Hospital do Coração
Verified email at hcor.com.br
Cited by 17449

[HTML][HTML] Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label …

…, AVS Macedo, B Bronhara, LP Damiani, LM Barbosa… - The Lancet, 2021 - thelancet.com
Background COVID-19 is associated with a prothrombotic state leading to adverse clinical
outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised …

Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis

…, O Berwanger, AB Cavalcanti, PF Dequin, B Du… - Jama, 2020 - jamanetwork.com
Importance Effective therapies for patients with coronavirus disease 2019 (COVID-19) are
needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced …

Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX …

BM Tomazini, IS Maia, AB Cavalcanti, O Berwanger… - Jama, 2020 - jamanetwork.com
Importance Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19)
is associated with substantial mortality and use of health care resources. …

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis

…, DLC Farias, JG PRATS, AB CAVALCANTI… - Jama, 2021 - jamanetwork.com
Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …

[HTML][HTML] Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

AB Cavalcanti, FG Zampieri, RG Rosa… - … England Journal of …, 2020 - Mass Medical Soc
Background Hydroxychloroquine and azithromycin have been used to treat patients with
coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these …

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

…, LM Ishihara, D Schneider, D de Souza, AB Cavalcanti… - bmj, 2021 - bmj.com
Objective To determine whether tocilizumab improves clinical outcomes for patients with
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial. …

Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19: a …

…, EL Cáceres, LF Reyes, LP Damiani, AB Cavalcanti… - Jama, 2021 - jamanetwork.com
Importance The effect of high-flow oxygen therapy vs conventional oxygen therapy has not
been established in the setting of severe COVID-19. Objective To determine the effect of high-…

Effect of intravenous fluid treatment with a balanced solution vs 0.9% saline solution on mortality in critically ill patients: the BaSICS randomized clinical trial

…, JA Kellum, LP Damiani, NB Da Silva, AB Cavalcanti… - Jama, 2021 - jamanetwork.com
Importance Intravenous fluids are used for almost all intensive care unit (ICU) patients.
Clinical and laboratory studies have questioned whether specific fluid types result in improved …

How strong is the evidence for the use of perioperative β blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials

…, VM Montori, M Bhandari, A Avezum, AB Cavalcanti… - Bmj, 2005 - bmj.com
… We therefore defined, a priori, cardiovascular death, bradycardia needing treatment, and
hypotension needing treatment (see appendix B on bmj.com… Articles by Alexandre B Cavalcanti

[HTML][HTML] Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil …

…, LV Rizzo, AS Neto, FR Machado, AB Cavalcanti - The Lancet, 2020 - thelancet.com
Background The efficacy and safety of azithromycin in the treatment of COVID-19 remain
uncertain. We assessed whether adding azithromycin to standard of care, which included …